uniQure (QURE) Faces AMT 130 Scrutiny, Is It Still 60% Undervalued?

Simply Wall St.10-30

uniQure (NasdaqGS:QURE) is under closer scrutiny after fresh questions around AMT-130 trial data prompted a securities investigation, putting the durability of its gene therapies and current valuation...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2679265013?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","is_english":true,"pubTime":"2026-10-30 13:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2679265013","market":"us","top_or_hot":-1,"title":"uniQure (QURE) Faces AMT 130 Scrutiny, Is It Still 60% Undervalued?","media":"Simply Wall St.","content":"<div>\n<p>uniQure (NasdaqGS:QURE) is under closer scrutiny after fresh questions around AMT-130 trial data prompted a securities investigation, putting the durability of its gene therapies and current valuation...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/uniqure-qure-faces-amt-130-scrutiny-is-it-still-60-undervalu\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>uniQure (QURE) Faces AMT 130 Scrutiny, Is It Still 60% Undervalued?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nuniQure (QURE) Faces AMT 130 Scrutiny, Is It Still 60% Undervalued?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-30 13:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/uniqure-qure-faces-amt-130-scrutiny-is-it-still-60-undervalu><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>uniQure (NasdaqGS:QURE) is under closer scrutiny after fresh questions around AMT-130 trial data prompted a securities investigation, putting the durability of its gene therapies and current valuation...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/uniqure-qure-faces-amt-130-scrutiny-is-it-still-60-undervalu\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/uniqure-qure-faces-amt-130-scrutiny-is-it-still-60-undervalu","article_id":"2679265013","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/uniqure-qure-faces-amt-130-scrutiny-is-it-still-60-undervalu","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2679265013","pubTimestamp":1793338656,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"uniQure (NasdaqGS:QURE) is under closer scrutiny after fresh questions around AMT-130 trial data prompted a securities investigation, putting the durability of its gene therapies and current valuation against book value under the spotlight for investors.\nMomentum around uniQure has swung sharply this year, with a 1-week share price return of 9.5% and a 30-day gain of 3.2% contrasting with a 90-day share price decline of 42%. The 1-year total shareholder return is down 62.7%, despite a very...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","AVRE":"Avantis Real Estate ETF","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","URE":"两倍做多房地产ETF-ProShares","BK4139":"生物科技","IDGT":"ISHARES U.S. DIGITAL INFRASTRUCTURE AND REAL ESTATE ETF","BK4084":"特种房地产投资信托","BK4219":"电信塔房地产信托","DFGR":"DIMENSIONAL GLOBAL REAL ESTATE ETF","REAI":"The Intelligent Real Estate ETF","DTCR":"Global X Data Center & Digital Infrastructure ETF","XLRE":"Real Estate Select Sector SPDR Fund","TRUR":"VanEck Real Estate TruSector ETF","WTRE":"WisdomTree New Economy Real Estate Fund","BYRE":"Principal Real Estate Active Opportunities ETF","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","SRVR":"PACER DATA & INFRASTRUCTURE REAL ESTATE ETF","VNQ":"不动产信托指数ETF-Vanguard","BK4588":"碎股","AMT":"美国电塔","HELS":"Hedgeye 130/30 Equity ETF","DTRE":"First Trust Alerian Disruptive Technology Real Estate ETF","CDIG":"City Different Investments Global Equity ETF","ICF":"不动产指数ETF-iShares","FREL":"Fidelity MSCI Real Estate Index ETF","BK4554":"元宇宙及AR概念","BK4581":"高盛持仓","PSR":"Invesco Active U.S. Real Estate ETF","QURE":"uniQure N.V.","CRED":"COLUMBIA RESEARCH ENHANCED REAL ESTATE ETF","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD"},"translate_title":"uniQure (QURE) 面临 AMT 130 审查，是否仍被低估 60%？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"REAI":0.6,"HELS":1.5,"IDGT":0.6,"URE":0.6,"BYRE":0.6,"DTCR":0.6,"WTRE":0.6,"SRVR":0.6,"PSR":0.6,"FREL":0.6,"TRUR":0.6,"CRED":0.6,"CDIG":0.65,"DFGR":0.6,"AMT":1.5,"XLRE":0.6,"VNQ":0.6,"ICF":0.6,"QURE":1.5,"DTRE":0.6,"AVRE":0.6},"content_text":"uniQure (NasdaqGS:QURE) is under closer scrutiny after fresh questions around AMT-130 trial data prompted a securities investigation, putting the durability of its gene therapies and current valuation against book value under the spotlight for investors. Momentum around uniQure has swung sharply this year, with a 1-week share price return of 9.5% and a 30-day gain of 3.2% contrasting with a 90-day share price decline of 42%. The 1-year total shareholder return is down 62.7%, despite a very large 3-year total shareholder return. This highlights how the latest AMT-130 scrutiny and securities investigation have quickly reshaped risk perception around a stock now trading at US$25.30 and already flagged as carrying a premium price to book value. Balance the uniQure story by scanning hand-picked biotech peers facing similar trial and valuation pressure through the 18 high quality undiscovered gems. uniQure now trades at US$25.30, while analyst and model estimates cluster much higher. Where does fair value really land across that spread, especially after this sharp swing in sentiment? AdvertisementMost Popular Narrative: 59.5% Undervalued Against a most-followed fair value estimate of $62.42, uniQure at $25.30 screens as heavily discounted, which puts the AMT-130 story and its projected cash flows at the center of any valuation debate.  The analysts have a consensus price target of $62.42 for uniQure based on their expectations of its future earnings growth, profit margins and other risk factors. In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $445.8 million, earnings will come to $20.0 million, and it would be trading on a PE ratio of 333.1x, assuming you use a discount rate of 7.9%.  What is behind that confidence gap in the forecasts and valuation spread, see 12 investors see uniQure as 59% undervalued. Result: Fair Value of $62.42 (UNDERVALUED) Still, if AMT-130 stumbles on regulatory review or if manufacturing shifts create supply disruptions, the uniQure narrative that underpins those valuation targets could unravel. Find out about the key risks to this uniQure narrative. Next Steps Sentiment around uniQure is clearly split, which is exactly why you may want to move quickly, review the full data set, and weigh both the downside and upside drivers for yourself with 2 key rewards and 1 important warning sign. Looking for more uniQure investment ideas? If uniQure has your attention, do not stop here. Broader context across other opportunities can sharpen your judgment and keep your watchlist one step ahead.  Target reliable cash generators by scanning companies with strong payouts and resilient income profiles through 7 dividend fortresses. Hunt for potential bargains trading below intrinsic worth by checking the 30 high quality undervalued stocks. Prioritise resilience by reviewing stocks that pass strict balance sheet and fundamentals filters in our list of solid balance sheet and fundamentals (23 results).  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if uniQure might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.1","shortVersion":"4.52.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2679265013","isCrawlerRequest":true}